Triple reuptake inhibitors

Triple reuptake inhibitors (TRIs) are a relatively new class of antidepressants which are currently undergoing clinical trials for treatment of depression, anxiety disorders and some personality disorders.

TRIs target all three of the brain's neurotransmitters serotonin, dopamine and noradrenaline.

Agomelatine
Novartis is currently progressing through phase 3 of clinical trials with Agomelatine, a drug developed by French pharmaceutical company Servier.